Media stories about OraSure Technologies (NASDAQ:OSUR) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.9265282938143 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of analysts recently weighed in on OSUR shares. BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, November 4th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of OraSure Technologies in a research report on Friday, October 20th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. OraSure Technologies currently has a consensus rating of “Buy” and a consensus price target of $18.21.

OraSure Technologies (OSUR) traded down $0.35 during trading hours on Friday, reaching $13.74. 1,172,898 shares of the company’s stock were exchanged, compared to its average volume of 871,565. The stock has a market cap of $854.53, a PE ratio of 27.14, a P/E/G ratio of 2.71 and a beta of 1.39. OraSure Technologies has a one year low of $8.21 and a one year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. The company had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.11 EPS. analysts forecast that OraSure Technologies will post 0.42 EPS for the current year.

In other OraSure Technologies news, insider Brian Smith sold 9,112 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $20.47, for a total value of $186,522.64. Following the completion of the transaction, the insider now directly owns 32,477 shares of the company’s stock, valued at approximately $664,804.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mara G. Aspinall acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was purchased at an average cost of $14.23 per share, with a total value of $71,150.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $71,150. The disclosure for this purchase can be found here. Over the last three months, insiders sold 61,110 shares of company stock valued at $1,362,463. 6.40% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/11/18/orasure-technologies-osur-receives-coverage-optimism-rating-of-0-08.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.